Email Artikel ini Review Artikel: Polimorfisme Gen Serotonin Mempengaruhi Pengobatan Risperidone dan Clozapine Pada Pasien Skizofrenia
Abstrak
Skizofrenia merupakan penyakit kejiwaan yang ditandai dengan halusinasi, delusi, kehilangan motivasi dan menarik diri dari lingkungan sosial. Adanya heterogenitas pada respon pengobatan skizofrenia pada setiap individu membuat strategi pengobatan menggunakan sistem trial and error. Strategi pengobatan ini sangat merugikan pasien mengingat efek samping obat yang mungkin terjadi. Salah satu kemungkinan terjadinya trial and error adalah adanya polimorfisme gen pada reseptor target obat, salah satunya ialah gen yang berhubungan dengan serotonin. Tujuan penulisan artikel review ini adalah untuk mengkaji pengaruh polimorfisme gen serotonin terhadap efek klinis pengobatan dengan risperidone dan clozapine. Metode dalam artikel review ini adalah penelusuran data dari berbagai artikel jurnal berbasis Pubmed dan Google Scholar dengan kata kunci “Polymorphism, Serotonin Gene, Risperidone, Clozapine”. Hasil dari review ini adalah adanya pengaruh yang diberikan polimorfisme gen serotonin terhadap efek klinis yang dihasilkan dari pengobatan risperidone dan clozapine, sehingga penulis menyimpulkan bahwa polimorfisme gen dapat menjadi salah satu penyebab terjadinya trial and error pada pengobatan skizofrenia.
Kata kunci: Clozapine, Polimorfisme, Risperidone, Serotonin, Skizofrenia.
Referensi
Picchioni, M. M. Scizophrenia. British Medical Journal. 2014; 335(7610): 91-95.
Lally J., MacCabe J. H. Antipsychotic Medication in Schizophrenia: A Review. British Medical Bulletin. 2015; 0 (0): 1-11.
Goldman, N., Glei, D. A., Lin, Y. H., Weinstein, M. The Serotonin Transporter Polymorphism (5-HTTLPR): Allelic Variation and Links With Depressive Symptoms. Depression and Anxiety. 2010; 27: 260-269.
Wooley, D. W., Shaw, E. A Biochemical and Pharmacological Suggestion About Certain Mental Disorders. Proceedings of The National Academy of Science of The USA. 1954; 40: 228-231.
Gaddum, J. H., Hameed, K. A. Drugs Which Antagonize 5-hydroxytryptamine. British Journal of Pharmacology. 1954; 9: 240-248.
Naughton, M., Mulrooney, J. B., Leonard, B. E. A Review of the Role of Serotonin Receptors in Psychiatric Disorders. Hum. Psychopharmacol. 2000; 15: 397-415.
Arranz M. J., Munro, J., Birkett, J., Bolonna A. A., Mancama, D., Sodhi M. Pharmacogenetic Prediction of Clozapine Respone. Lancet. 2000; 355: 1615-1616.
Vandermaelen C. P., Matheson, G. K.,Wilderman R. C. Inhibition of Serotonergic Dorsal Raphe Neurons by Systemic and Iontophoretic Administration of Buspirone, a non-benzodiazepine Anxiolytic Drug. Eur J Pharmacol. 1986; 129: 123- 130.
Reynolds G. P., Arranz B., Templeman L. A., Fertuzinhos S., San L. Effect of 5-HT1A Receptor Gene Polymorphism on Negative and Depressive Symptom Respone to Antipsychotic Treatment of Drug-Naive Psychotic Patients. Am J Psychiatry. 2006; 163: 1826-1829.
Wang L., Fang C., Zhang A et al. The 1019C/G Polymorphism of the 5-HT1A Receptor Gene is Associated with Negative Symptom Response to Risperidone Treatment in Schizophrenia Patients. J. Psychopharmacol. 2008; 22 (8): 904-909.
Mössner R., Schuhmacher A., Kühn K. U. et al. Functional Serotonin 1A Receptor Variant Influences Treatment Response to Atypical Antipsychotics in Scizhophrenia. Pharmacogenet. Genomics. 2009; 19 (1): 91-94.
Lemonde S., Turecki G., Bakish D., Du L., Hrdina P. D., bown C. D. Impaired Repression at a 5-hydroxytryptamine 1A receptor Gene Polymorphism Associated with Major Depression and Suicide. J Neurosci. 2003; 23: 8788-8799.
Meltzer H. Y., Li Z., Kaneda Y., Ichikawa J. Serotonin Receptors: Their Key Role in Drugs to Treat Schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2003; 27 (7): 1159-1172.
Staner L., Kempenaeras C., Simonnet M. P. et al. 5-HT2A Receptor Antagonism and Slow-Wave Sleep in Major Depression. Acta Psychiatr Scand. 1992; 86: 133-137.
Lane H. Y., Chang Y. C., Chiu C. C., Chen M. L., Hsieh M. H., Chang W. H. Association of Risperidone Treatment Response with a Polymorphism in the 5-HT (2A) Receptor Gene. Am. J. Psychiatry. 2002; 159 (9): 1593-1595.
Arranz M. J., Munro J., Sham P., Kirov G., Murray R. M., Collier D. A et al. Meta-analysis of Studies on Genetic Variation in 5-HT2A Receptors and Clozapine Responese. Schizophr Res. 1998; 32: 93-99.
Arranz M. J., Collier D. A., Sodhi M., Ball D., Roberts G., Price J et al. Association Between Clozapine Response and Allelic Variation in the 5-HT2A Receptor Gene. Lancet. 1995; 346: 281-282.
Nothen M. M., Rietschel M., Erdmann J., Oberlander H., Moller H. J., Nober D et al. Genetic Variation of the 5-HT2A Receptor and Response to Clozapine. Lancet. 1995; 346: 908-909.
Masellis M., Paterson A. D., Badri F., Lerberman J. A., Meltzer H. Y., Cavazzoni P. et al. Genetic Variation of 5-HT2A Receptor and Response to Clozapine. Lancet. 1995; 346: 1108.
Malhotra A. K., Goldman D., Ozaki N., Breier A., Buchanan R., Pickar D. Lack of Association Between Polymorphism in the 5-HT2A Receptor Gene and the Antipsychotic Response to Clozapine. Am. J. Psychiatry. 1996; 153: 1092-1094.
Lin C. H., Tsai S. J., Yu Y. W., Song H. L., Tu P. C., Sim C. B et al. No Evidence for Association of Serotonin-2A Receptor Variant (102T/C) with Schizophrenia or Clozapine Response in a Chinese Population. Neuroreport. 1999; 10: 57-60.
Kim B., Choi E. Y., Kim C. Y., Song K., Joo Y. H. Could HTR2A T102C and DRD3 Ser9Gly Predict Clinical Improvement in Patients With acutely Ecaverbated Schizophrenia? Results from Treatment Responses to Risperidone in a Naturalistic Setting. Hum. Psychopharmacol. 2008; 23 (1): 61-67.
Hamdani N., Bonniere M., Ades J., Hamon M., Boni C., Gorwood P. Negative Symptoms of Schizophrenia Could Explain Discrepant data in the Association Between the 5-HT2A Receptor Gene and Response to Antipsychotics. Neurosci Lett. 2005; 377: 69-74.
Arranz M. J., Munro J., Owen M. J.m Spurlock J., Sham P., Zhao J. et al. Evidence for Association between Polymorphism in the Promoter and Codung Regions of the 5-HT2A Receptro Gene and Response to Clozapine. Mol Psychiatry. 1998; 3: 61-66.
Arranz M. J., Collier D. A., Munro J. Sham P., Kirov G., Sodhi M. et al. Analysis of a Structural Polymorphism in the 5-HT2A Receptor and Clinical Response to Clozapine. Neuroci Lett. 1996; 217: 177-178.
Masellis M., Basile V. S., Meltzer H. Y., Lieberman J. A., Sevy S., Macciardi F. et al. Serotonin Subtype 2 Receptor Genes and Clinical Response to Clozapine in Schizophrenia Patients. Neuropsychopharmacology. 1998 ; 19: 123-132.
Tecott L. H., Sun L. M., Akana S. F. et al. Eating Disorder and Epilepsy in Mice Lacking 5-HT2C Serotonin Receptor. Nature. 1995; 374 (6522): 542-546.
Smith S. R., Weissman N. J., Anderson C. M. et al. Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management. N. Engl. J. Med. 2010; 363 (3): 245-256.
Reynolds G. P., Yao Z., Zhang X., Sun J., Zhang Z. Pharmacogenetics of Treatment in First-episode Schizophrenia: D3 and 5-HT2C Receptor Polymorphism Separately Associate with Positive and Negative Symptom Response. Eur. Neuropsychopharmacol. 2005; 15(2): 143-151.
Lane H. Y., Liu Y. C., Huang C. L., Chang Y. C., Wu P. L., Lu C. T., Chang W. H. Risperidone-related Weight Gain Genetic and Nongenetic Predictors. J. Clin Psychopharmacol. 2006.; 26: 128-134.
Arranz M. J., Munro J., Birkett J., Bolonna A. A., Mancama D., Sodhi M. et al. Pharmacogenetic Prediction of Clozapine Response. Lancet. 2000; 355: 1615-1616.
Sodhi M., Arranz M. J., Curtis D., Ball D., Sham P., Roberts G. et al. Association Between Clozapine Response and Allelic Cariation in the 5-HT2C Receptor Gene. Neuroreport. 1995; 7: 169-172.
Rietschel M., Naber D., Fimmers R., Moeller H. J., Propping P., Noethen M. M. Efficacy and Side-effects of Clozapine not Associated with Variation in the 5-HT2C Receptor. Neuroreport. 1997; 8: 1999-2003.
Gutierrez B., Arranz M. J., Huezo-Diaz P., Dempster D., Matthiasson P., Travis M. et al. Novel Mutation in 5-HT3A dan 5-HT3B receptor Genes not Associated with Clozapine Response. Schizophr Res. 2002; 58: 93-97.
Birkett J. T., Arranz M. J., Munro J., Osbourn S., Kerwin R. W., Collier D. A. Association analysis of the 5-HT5A gene in Depression, Psychosis and Anti psychotic Response. Neuroreport. 2000; 11: 2017-2020.
Wei Z., Wang L., Xuan J. et al. Association Analysis of Serotonin Receptor 7 Gene (HTR7) and Risperidone Response in Chinese Schizophrenia Patients. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2009; 33 (3): 547-551.
Hoyer D., Clarke D. E., Fozard J. R. et al. International Union of Pharmacology Classification of Receptors for Serotonin. Pharmacol. 1994; 46: 157-203.
Lane H. Y., Lin C. C., Huang C. H., Chang Y. C., Hsu S. K., Chang W. H. Risperidone Response and 5-HT6 Receptor Gene Variance: Genetic Association Analysis with Adjustment for Nongenetic Confounders. Schizophr Res. 2004; 67: 63-70.
Yu Y. W. Y., Tsai S. J., Lin C. H., Hsu C. P., Ynakg K. H., Hong C. J. Serotonin-6 Receptor Variant (C267T) and Clinical Response to Clozapine. Neuroreport. 1999; 10: 1231-1233.
Masellis M., Basile V. S., Meltzer H. Y., Lieberman J. A., Sevy S., Goldman D. et al. Lack of Association Between the T-C267 Serotonin 5-HT6 Receptor Gene (HTR6) Polymorphism and Prediction of Response to Clozapine in Schizophrenia. Schizophr Res. 2001; 47: 49-58.
Lesch K. P., Bengel D., Heils A., Sabol S. Z., Greenberg B. D., Petri S., Benjamin J., Muller C. R., Hamer D. H., Murphy D. L. Association of Anxiety Related Traits with a Polymoprhism in the Serotonin Transporter Gene Regulatory Region. Science. 1996; 274: 1527-1531.
Bourgon V. J., Arranz M. J., Mata I., Pelayo-Terán J. M., Iglesias R. P., González L. M., Marín E. C., Barquero J. L. V., Facorro B. C. Serotonin Transporter Polymorphism and Early Response to Antipsychotic Treatment in First Episode of Psychosis. Psychiatry Research. 2010; 175: 189-194.
Wang L., Yu L., He G. et al. Response of Risperidone Treatment may be Associated with Polymorphism of HTT Gene in Chinese Schizophrenia Patients. Neurosci. Lett. 2007; 414 (1): 1-4.
Tsai S. J., Hong C. J., Yu Y. W., Lin C. H. Song H. L., Lai H. C. et al. Association Study of a Functional Serotonin Transporter Gene Polymorphism with Schizophrenia, psychopathology and Clozapine Response. Schizophr Res. 2000; 44 (3): 177-181.
Arranz M. J., Bolonna A. A., Munro J., Curtis C. J., Collier D. A., Kerwin R. W. The Serotonin Transporter and Clozapine Response. Mol Psychiatry. 2000; 5: 124-130.
Kaiser R., Tremblay P. B., Schmider J., Henneken M., Dettling M., Muller-Oerlinghausen B. et al. Serotonin Transporter Polymorphism: No Association with Response to Antipsychotic Treatment, But Association with Schizoparanoid and Residual Subtypes of Schizophrenia. Mol Psychiatry. 2001; 6: 179-185.
DOI: https://doi.org/10.24198/jf.v16i1.17348
DOI (PDF): https://doi.org/10.24198/jf.v16i1.17348.g8611
DOI (PDF): https://doi.org/10.24198/jf.v16i3.17348.g8969
Refbacks
- Saat ini tidak ada refbacks.
Sitasi manajer:
Jurnal ini diindeks dalam:
Farmaka by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Copyright © 2013 Jurnal Farmaka - All Right Reserved